Viracta Therapeutics (NASDAQ:VIRX) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Viracta Therapeutics (NASDAQ:VIRX) in a research note released on Tuesday, Benzinga reports. The brokerage currently has a $4.00 price target on the stock.

Viracta Therapeutics Stock Performance

NASDAQ:VIRX opened at $0.91 on Tuesday. Viracta Therapeutics has a one year low of $0.43 and a one year high of $2.38. The firm has a market cap of $35.70 million, a price-to-earnings ratio of -0.69 and a beta of 0.93. The firm’s fifty day moving average is $0.91 and its two-hundred day moving average is $0.70.

Viracta Therapeutics (NASDAQ:VIRX) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.05). As a group, equities research analysts predict that Viracta Therapeutics will post -1.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Viracta Therapeutics

Several hedge funds have recently modified their holdings of VIRX. Millennium Management LLC purchased a new stake in shares of Viracta Therapeutics during the 2nd quarter worth about $1,227,000. Vanguard Group Inc. boosted its stake in shares of Viracta Therapeutics by 22.8% during the 3rd quarter. Vanguard Group Inc. now owns 1,114,368 shares of the company’s stock worth $4,759,000 after acquiring an additional 207,108 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in Viracta Therapeutics in the 3rd quarter valued at about $625,000. BlackRock Inc. lifted its stake in Viracta Therapeutics by 22.2% in the 3rd quarter. BlackRock Inc. now owns 662,600 shares of the company’s stock valued at $2,830,000 after buying an additional 120,169 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new position in Viracta Therapeutics in the 4th quarter valued at about $87,000. 31.37% of the stock is owned by hedge funds and other institutional investors.

Viracta Therapeutics Company Profile

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.